D. Beshore

发表

Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency.

A. D. Rodrigues, E S Walsh, J B Gibbs, 2001, Journal of medicinal chemistry.

Preparation of Ethyl 5-Iodo-1H-indole- 2-carboxylate

D. Beshore, C. Dinsmore, 2003 .

Novel M1 allosteric ligands: a patent review

S. Kuduk, D. Beshore, 2012, Expert opinion on therapeutic patents.

Redefining the Histone Deacetylase Inhibitor Pharmacophore: High Potency with No Zinc Cofactor Interaction

P. Coleman, Christopher D. Cox, D. Klein, 2021, ACS medicinal chemistry letters.

Building a Culture of Medicinal Chemistry Knowledge Sharing.

Andrew M Haidle, I. Raheem, Yeon-Hee Lim, 2022, Journal of medicinal chemistry.

High-Throughput Agonist Shift Assay Development for the Analysis of M1-Positive Allosteric Modulators

Michael F. Finley, J. Hermes, V. Uebele, 2017, SLAS discovery : advancing life sciences R & D.

Atrial Antifibrillatory Effects of Structurally Distinct IKur Blockers 3-[(Dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-Phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in Dogs with Underlying Heart Failure

N. Liverton, L. Kiss, C. Regan, 2008, Journal of Pharmacology and Experimental Therapeutics.

Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation.

James I. Fells, D. Klein, R. Myers, 2020, Bioorganic & medicinal chemistry letters.

Recent advances in the synthesis of diketopiperazines

D. Beshore, C. Dinsmore, 2002 .

Efficient synthesis of 1-heterocyclic-3-aminopyrrolidinones

T. Williams, I. M. Bell, S. N. Gallicchio, 2000 .

A Phenotypic Screen Identifies Potent DPP9 Inhibitors Capable of Killing HIV-1 Infected Cells.

W. Shipe, I. Cornella-Taracido, An Chi, 2022, ACS chemical biology.

Construction of 5,6-Ring Fused 2-Pyridones: An Effective Annulation Tactic Achieved in Water.

Amos B. Smith, D. Beshore, Onur Atasoylu, 2009, Synlett : accounts and rapid communications in synthetic organic chemistry.

Total syntheses of (+)-lyconadin A and (-)-lyconadin B.

Amos B. Smith, D. Beshore, 2007, Journal of the American Chemical Society.

Construction of 5,6-Ring-Fused 2-Pyridones: An Effective Annulation Tactic Achieved in Water.

Amos B. Smith, D. Beshore, Onur Atasoylu, 2010 .

Preparation of 2,4,5-trisubstituted pyrazolo[4,3-c]quinolin-3-ones

R. M. Dipardo, S. Kuduk, D. Beshore, 2010 .

Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation.

Kenneth D Anderson, K. K. Nanda, N. Liverton, 2006, Journal of medicinal chemistry.

SYNTHESES AND TRANSFORMATIONS OF PIPERAZINONE RINGS. A REVIEW

D. Beshore, C. Dinsmore, 2002 .

2,5-Disubstituted Pyrazolo[4,3-c]cinnolin-3-ones

R. M. Dipardo, S. Kuduk, D. Beshore, 2017 .

Efficient synthesis of unsymmetrical 1,4-disubstituted-2,3-diketopiperazines via tandem reductive amination–cyclization

D. Beshore, C. Dinsmore, 2000 .

Preparation of substituted piperazinones via tandem reductive amination-(N,N'-acyl transfer)-cyclization.

D. Beshore, C. Dinsmore, 2002, Organic letters.

The lyconadins: enantioselective total syntheses of (+)-lyconadin A and (-)-lyconadin B.

Amos B. Smith, D. Beshore, 2008, Journal of the American Chemical Society.

Evaluation of amino acid-based linkers in potent macrocyclic inhibitors of farnesyl-protein transferase.

J. Davide, N. Kohl, R. Lobell, 2001, Bioorganic & medicinal chemistry letters.

3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.

A. D. Rodrigues, J Christopher Culberson, Ronald Robinson, 2002, Journal of medicinal chemistry.

Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel.

N. Liverton, C. Claiborne, R. Spencer, 2010, Bioorganic & medicinal chemistry letters.

Preclinical to Human Translational Pharmacology of the Novel M1 Positive Allosteric Modulator MK-7622

Steven V. Fox, J. Uslaner, S. Kuduk, 2018, The Journal of Pharmacology and Experimental Therapeutics.

MK-7622: A First-in-Class M1 Positive Allosteric Modulator Development Candidate.

J. Fuerst, M. Seager, S. Kuduk, 2018, ACS medicinal chemistry letters.

SAR studies on carboxylic acid series M(1) selective positive allosteric modulators (PAMs).

S. Kuduk, Scott D Kuduk, Douglas C Beshore, 2014, Current topics in medicinal chemistry.

Informing the Selection of Screening Hit Series with in Silico Absorption, Distribution, Metabolism, Excretion, and Toxicity Profiles.

Andreas Verras, Robert P Sheridan, J Christopher Culberson, 2017, Journal of medicinal chemistry.

Conserved allosteric inhibitory site on the respiratory syncytial virus and human metapneumovirus RNA-dependent RNA polymerases

J. Howe, M. Eddins, R. Fearns, 2023, Communications biology.

Microbial biotransformation – an important tool for the study of drug metabolism

R. D. de Vries, Natasa Pajkovic, R. Helmy, 2018, Xenobiotica; the fate of foreign compounds in biological systems.

Identification of a methoxynaphthalene scaffold as a core replacement in quinolizidinone amide M(1) positive allosteric modulators.

S. Kuduk, K. Koeplinger, G. Hartman, 2014, Bioorganic & medicinal chemistry letters.

Hydroxy cycloalkyl fused pyridone carboxylic acid M(1) positive allosteric modulators.

R. M. Dipardo, M. Seager, S. Kuduk, 2010, Bioorganic & medicinal chemistry letters.